This is the authors' abstract. We don't add key points for this paper.
Background The introduction of second generation antipsychotics provided mental health professionals effective first line agents for the treatment of schizophrenia and other psychoses, which cause less side effects than first generation ones. The expanding use of these drugs is strongly correlated with the development of metabolic syndrome in the long-term, resulting in serious medical comorbidities of psychotic patients, such as cardiovascular events.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Peritogiannis et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: